Please login to the form below

Not currently logged in
Email:
Password:

sunitinib

This page shows the latest sunitinib news and features for those working in and with pharma, biotech and healthcare.

Merck, Eisai’s Keytruda/Lenvima regimen scores full approval in endometrial cancer

Merck, Eisai’s Keytruda/Lenvima regimen scores full approval in endometrial cancer

In June, Merck and Eisai also announced that the Keytruda plus Lenvima combination treatment improved outcomes when compared to Pfizer’s Sutent (sunitinib) on a measure of health-related quality of ... Previously, Merck and Eisai reported that Keytruda

Latest news

More from news
Approximately 2 fully matching, plus 76 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • CABOSUN trial of cabozantinib – could it change how we treat frontline renal-cell carcinoma?

    In the CABOSUN trial, cabozantinib was compared to sunitinib in treatment naive poor and intermediate risk renal-cell carcinoma (RCC) patients. ... In the  CABOSUN trial, cabozantinib was compared to sunitinib in treatment naive poor and intermediate

  • Oncology drugs under AMNOG

    Pfizer’s Inlyta (axitinib) was approved in kidney cancer for patients pre-treated with either another targeted therapy, Sutent (sunitinib), or with older drugs called cytokines. ... Consistent with EMA market authorisations for other kidney cancer

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Medscape Education Global

Medscape delivers dynamic, innovative education to optimize learner engagement and patient outcomes worldwide....

Latest intelligence

Our Top 5 Pharma Picks From Cannes Lions
Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
The Evolving Role of the Sales Rep
The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
Measure your omnichannel maturity with our new tool
Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....